Marijuana Rescheduling and DOT Drug Testing: What Changes, What Doesn't

What the DEA Marijuana Rescheduling Proposal Actually Says

In May 2024, the U.S. Drug Enforcement Administration published a proposed rule under DEA docket DEA-1362 to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA). This was the most significant proposed change to marijuana's federal legal status in decades, and it set off a wave of misinformation about what it means for industries regulated by federal agencies — including the transportation sector.

Schedule I substances are classified as having no accepted medical use and a high potential for abuse. Schedule III substances are recognized as having accepted medical use with moderate to low potential for dependence. Other Schedule III substances include anabolic steroids and ketamine. The rescheduling, if finalized, would mean federal agencies could no longer prosecute simple possession under the same standards — and it would open the door for certain federal medical research programs.

What the rescheduling proposal does not do is legalize recreational marijuana federally, remove marijuana from the Controlled Substances Act entirely, or modify any agency-specific regulations that independently prohibit marijuana use. The DOT's drug testing program falls squarely into that last category.

The DOT's Pipeline and Hazardous Materials Safety Administration (PHMSA), Federal Aviation Administration (FAA), Federal Motor Carrier Safety Administration (FMCSA), Federal Transit Administration (FTA), and Federal Railroad Administration (FRA) have all issued consistent guidance: their drug testing programs operate under independent statutory authority and are not affected by changes to the Controlled Substances Act's scheduling of marijuana. This consistency across agencies is not coincidental — it reflects a deliberate regulatory architecture in which Congress gave each safety agency independent authority over its own testing programs, precisely to insulate them from changes in the criminal law scheduling framework.

This matters because carriers, drivers, and even some compliance professionals have incorrectly interpreted the rescheduling proposal as a signal that marijuana use will soon be permitted for CDL holders. That interpretation is incorrect and potentially dangerous — both for road safety and for carrier liability exposure. A carrier that relaxes its drug testing program based on a news headline about rescheduling, only to have a driver subsequently test positive and be found operating in violation of 49 CFR Part 382, has compounded the original testing failure with a second one: a failure of the compliance oversight program itself.

The timeline for any actual regulatory change — if one were ever to occur — would involve DOT publishing a Notice of Proposed Rulemaking, a public comment period of 60–90 days, analysis of comments, and publication of a Final Rule with an effective date. That process typically takes 18–36 months from initiation. As of March 2026, DOT has not initiated any such rulemaking. The current rules apply in full.

Why DOT Drug Testing Is Completely Separate From Drug Scheduling

The fundamental misunderstanding behind most of the rescheduling confusion is the assumption that DOT drug testing requirements flow from the Controlled Substances Act schedule. They do not. DOT drug testing authority flows from the Omnibus Transportation Employee Testing Act of 1991, which Congress passed independently of the CSA. This law directed DOT to establish mandatory drug and alcohol testing requirements for safety-sensitive transportation employees — and it gave DOT independent regulatory authority to define what substances are tested for.

Under that authority, DOT promulgated 49 CFR Part 40 — the foundational regulation governing all DOT-mandated drug and alcohol testing across all transportation modes. Part 40 establishes collection procedures, laboratory standards, Medical Review Officer (MRO) requirements, and what substances must be included in the standard 5-panel test. Marijuana (specifically, THC metabolites) appears on the DOT 5-panel test because DOT decided it should be there — not because it is a Schedule I substance.

If DOT wanted to remove marijuana from its 5-panel test, it would need to conduct its own rulemaking — a separate and independent process from the DEA rescheduling action. That rulemaking has not been initiated. DOT has been explicit: the agency does not plan to remove marijuana from its testing panel, and it does not recognize state medical or recreational marijuana laws as a defense to a positive DOT drug test.

This architecture is intentional. Congress wanted safety-sensitive transportation workers — people operating 80,000-pound commercial vehicles at highway speeds — to be held to a consistent federal standard regardless of where they live or what their state legislature has decided about recreational drug policy. That policy judgment remains intact.

DOT Testing Requirements Under 49 CFR Part 40 (Current)

For FMCSA-regulated motor carriers, the drug and alcohol testing program is governed by two regulations working in tandem: 49 CFR Part 40 (the technical and procedural rules for all DOT testing) and 49 CFR Part 382 (the FMCSA-specific rules for commercial motor vehicle operators). Together, these regulations require six distinct types of testing.

The DOT 5-panel urine test screens for: marijuana (THC metabolites), cocaine metabolites, opiates (codeine, morphine, heroin), amphetamines (including methamphetamine and MDMA), and phencyclidine (PCP). The cutoff levels are set in 49 CFR Part 40 Subpart F. For marijuana, the initial test cutoff is 50 ng/mL and the confirmatory cutoff using GC/MS is 15 ng/mL.

All DOT drug testing must use SAMHSA-certified laboratories. Specimens must be collected at qualified collection sites following chain-of-custody procedures. Results are reviewed by a licensed Medical Review Officer (MRO) who has authority to verify negative, positive, cancelled, or adulterated/substituted results. An employer cannot simply accept a raw lab result — MRO review is mandatory.

The FMCSA Drug and Alcohol Clearinghouse: What Changed in 2020

The FMCSA Drug and Alcohol Clearinghouse launched on January 6, 2020, fundamentally changing how drug and alcohol violations are tracked and shared across the industry. Before the Clearinghouse, a driver who failed a drug test at one carrier could simply move to another carrier without disclosing the violation — the paper-based self-reporting system had obvious gaps. The Clearinghouse closed them.

The Clearinghouse is a secure online database maintained by FMCSA that contains real-time information about CDL driver drug and alcohol violations. Every motor carrier, Medical Review Officer, Substance Abuse Professional, and third-party administrator (C/TPA) involved in a DOT violation is required to report to the Clearinghouse. The system creates a complete, linked record of every violation and the subsequent return-to-duty process.

Employers have two mandatory Clearinghouse query obligations. Before a CDL driver performs safety-sensitive functions for the first time, the employer must conduct a full query — which requires the driver's electronic consent and reveals all violations and RTD status. After the initial hire, employers must conduct a limited query (which does not require separate consent if covered in the hiring documentation) for each CDL driver at least once per year.

If a limited query returns a result — meaning there is information in the Clearinghouse about that driver — the employer must immediately conduct a full query before allowing the driver to continue performing safety-sensitive functions. The driver cannot drive until the employer has reviewed the full record and determined the driver is eligible.

The Clearinghouse does not distinguish between marijuana and other substances in terms of the reporting requirements or consequences. A positive marijuana test triggers the same Clearinghouse entry, the same SAP referral requirement, and the same RTD process as a positive cocaine or methamphetamine test. Rescheduling does not change any of this.

What Happens When a Driver Tests Positive for THC

When a DOT-regulated drug test returns a verified positive result for marijuana — or any other substance on the 5-panel — the consequences are immediate, mandatory, and well-defined. There is no discretion for the employer. There is no grace period. There is no state-law exception. The sequence is as follows.

Step 1: Immediate removal from safety-sensitive duty. The moment the employer receives the verified positive result from the MRO, the driver must be removed from all safety-sensitive functions. This means no driving, no operating equipment, no dispatching from a moving vehicle. The employer cannot wait until the end of a run, cannot let the driver "finish the week," and cannot allow the driver to drive home from the terminal.

Step 2: SAP referral. The employer must provide the driver with a list of DOT-qualified Substance Abuse Professionals. The employer cannot choose the SAP for the driver — the driver selects their own SAP from the provided list. The SAP will evaluate the driver face-to-face, determine whether treatment or education is required, and prescribe a specific course of action. The SAP's recommendations are not optional.

Step 3: Treatment and education. The driver must complete all treatment or education recommended by the SAP before the return-to-duty process can begin. The employer has no visibility into or control over what the SAP recommends — it may be a single class or multi-month residential treatment. The employer's only obligation at this stage is to not allow the driver to return to safety-sensitive duty.

Step 4: Return-to-duty test. After the SAP confirms the driver has completed the prescribed program, the driver takes a return-to-duty drug test. This test must be conducted under direct observation — the collection site observer must watch the collection process. A negative result allows the driver to return to duty.

Step 5: Follow-up testing. Even after returning to duty, the driver is subject to a mandatory follow-up testing program. The minimum is 6 unannounced direct-observation tests in the first 12 months. The SAP can extend this to a maximum of 5 years. These tests are in addition to — not a substitute for — regular random testing. The employer must track the schedule and ensure the tests are completed.

The entire process — from positive test to full Clearinghouse resolution — typically takes 6 to 18 months. During that entire period, the driver cannot legally drive a commercial motor vehicle under your authority or any other carrier's authority. Any carrier that queries the Clearinghouse will see the unresolved violation and must refuse to hire the driver into a safety-sensitive role.

State Marijuana Laws vs Federal DOT Rules: No Conflict Resolution

As of March 2026, 47 states have legalized some form of marijuana use — either medical, recreational, or both. Every single one of those state laws contains a carve-out or is otherwise inapplicable to federally regulated workers. But even for states that have not explicitly written federal worker exceptions into their marijuana laws, the legal answer is the same: federal law preempts state law for DOT-regulated employees.

The Supremacy Clause of the U.S. Constitution establishes that federal law is the supreme law of the land. Where federal and state law conflict, federal law prevails. DOT's drug testing requirements are federal regulations. A state's decision to legalize marijuana for recreational or medical purposes cannot override a federal regulation requiring its prohibition in safety-sensitive transportation roles. This is not a close legal question.

The state vs. federal tension is real for workers who are not in safety-sensitive federally regulated roles. Employers in those contexts may have complex legal obligations related to state marijuana protections. But for CDL drivers and other safety-sensitive transportation workers, the legal landscape is unambiguous. Federal DOT testing requirements apply. State law is irrelevant.

One area where state law does interact with DOT testing is the workplace accommodation question. Some states — including Connecticut, New Jersey, New York, and others — have passed laws protecting workers from adverse employment action based solely on off-duty marijuana use or positive marijuana tests. Legal experts have noted that these protections likely do not apply to safety-sensitive DOT-regulated positions, but carriers operating in these states should consult employment counsel about their non-DOT-regulated positions.

2026 Compliance Requirements for Your Drug Testing Program

Regardless of where the DEA rescheduling proceeding goes, your compliance obligations for 2026 are unchanged. FMCSA has not published any interim guidance modifying testing requirements, and no pending rulemaking would reduce the current obligations. The following checklist reflects the requirements under 49 CFR Part 382 and 49 CFR Part 40 as currently in force. Carriers should treat each item as a binary compliance obligation, not an aspirational goal.

The checklist is organized by compliance area. Each area maps to a section of 49 CFR Part 382 that FMCSA investigators use during compliance reviews. Gaps in any area are individually citable violations.

One compliance area that often creates problems is the 3-year prior employer inquiry. Before putting a CDL driver into safety-sensitive service, you must contact all DOT-regulated employers who employed the driver in a safety-sensitive capacity within the past 3 years and request their drug and alcohol testing history. This is separate from the Clearinghouse query. You must document your attempt — including non-responses — and retain the records. Carriers who skip this step because they "couldn't reach" a prior employer are still expected to document the attempt and follow up.

Another frequently missed requirement is the annual MIS report. Under 49 CFR Part 382.403, employers are required to submit an annual Management Information System (MIS) report summarizing their drug and alcohol testing results. The report is submitted to FMCSA on a prescribed form and covers the number of tests administered, results by type, and violations. FMCSA typically issues the reporting instructions in January each year. Carriers that miss the submission deadline or submit incomplete reports face compliance review risk.

How FileFlo Manages Drug Testing Documentation

Drug and alcohol testing documentation is one of the highest-risk areas in a DOT compliance review. FMCSA investigators specifically look for gaps in pre-employment testing records, incomplete random testing logs, missing Clearinghouse query evidence, and unresolved Clearinghouse violations that should have triggered immediate removal. The consequences for documentation failures are not limited to fines — they are evidence in negligent entrustment cases.

FileFlo manages the document infrastructure that keeps your drug and alcohol testing program audit-ready year-round:

The bottom line on marijuana rescheduling is straightforward: nothing changes for your drug and alcohol testing program. The DEA process is separate from DOT authority. DOT has been clear in multiple public statements that it will not change its testing requirements based on rescheduling. CDL drivers who use marijuana — regardless of state law, medical authorization, or CBD product labeling — remain subject to the same testing rules they always have been.

What this moment does represent is an opportunity to audit your current drug testing program. Many carriers are running programs with documentation gaps that would create significant liability in an FMCSA compliance review. The rescheduling conversation is a useful prompt to ensure your records are complete, your Clearinghouse queries are current, and your random testing program is actually running at the required rates.

Common Drug Testing Documentation Failures That Trigger FMCSA Penalties

FMCSA compliance reviews examine drug and alcohol testing programs as one of six rated compliance factors. Investigators follow a structured review process that checks for specific documentation — and the most common failures are not exotic or obscure. They are the same gaps that appear across hundreds of reviews every year: programs that exist on paper but are not actually running, Clearinghouse queries that were never completed, and random testing pools that include drivers who should have been removed.

Understanding the most commonly cited violations helps carriers prioritize their compliance audits. The following categories represent the highest-frequency documentation failures found during FMCSA compliance reviews of drug and alcohol testing programs.

What CDL Drivers Need to Know About Rescheduling

Much of the confusion about marijuana rescheduling has originated with drivers, not carriers. Drivers who have used marijuana in legal states — or who have been following the news about federal legalization efforts — have sometimes concluded that the regulatory environment has already changed or is changing imminently. Carriers need to proactively communicate to their driver workforce that nothing has changed and nothing is expected to change in the near term.

The following are the factual statements that every CDL driver subject to DOT drug testing should understand clearly.

Proactively distributing updated driver communications about the rescheduling and DOT testing is a defensible compliance action. If a driver later claims they were confused by news coverage of rescheduling, a carrier that can document clear, contemporaneous communication to its drivers is in a much stronger position than one that assumed drivers would read the regulatory fine print themselves.

Choosing and Managing a C/TPA for Your Drug Testing Program

Most small and mid-size motor carriers manage their DOT drug and alcohol testing program through a Consortium/Third-Party Administrator (C/TPA). A C/TPA handles the mechanics of the random testing program: maintaining the pool, making random selections, scheduling collections, and often managing Clearinghouse reporting. Choosing the right C/TPA and actively managing the relationship are compliance obligations in themselves — carriers cannot simply contract with a C/TPA and consider themselves compliant.

Under 49 CFR Part 40.15, the employer remains responsible for compliance with the DOT testing requirements regardless of what the C/TPA does or fails to do. A C/TPA that miscounts your driver pool, selects drivers outside their required testing window, or fails to submit collections to a SAMHSA-certified laboratory has caused a compliance failure — but it is the employer who faces the FMCSA penalty.

The rescheduling conversation is a reminder that regulatory changes affecting your drug testing program will always originate at the federal level — and will always be communicated through FMCSA guidance, Federal Register notices, and DOT official positions before any change takes effect. Carriers should not rely on news coverage, industry rumor, or driver interpretation of political developments to modify their compliance programs. The authoritative sources are FMCSA.dot.gov, the Federal Register, and your DOT-qualified compliance counsel.

The Real Cost of a Failed Drug Testing Program

Beyond the regulatory penalties, there is a broader financial and liability calculus that makes a well-documented drug testing program one of the highest-ROI compliance investments a motor carrier can make. Carriers who discover they have systematic gaps in their testing programs — after an accident triggers an FMCSA investigation — face costs that dwarf the operational investment required to maintain a compliant program.

The math is straightforward. A fully compliant drug and alcohol testing program for a 10-truck fleet costs roughly $3,000–6,000 annually in direct expenses. A single FMCSA compliance review finding systematic testing failures can generate $50,000 or more in penalties. A single accident involving a driver whose testing records are not current can generate litigation costs and verdicts that exceed the carrier's annual revenue. Compliance is not overhead — it is risk management with a strongly positive ROI.

The marijuana rescheduling debate will continue to evolve. Congress may pass additional legislation. DOT may ultimately initiate its own rulemaking. State laws will continue to change. But until there is a specific, published, effective-date change to 49 CFR Part 40 or 49 CFR Part 382, every CDL driver and every FMCSA-regulated motor carrier operates under the same drug and alcohol testing rules that have governed the industry for three decades. The Clearinghouse continues to record violations. The 50% random drug testing rate remains in effect. A positive THC test still means immediate removal from safety-sensitive duty. The rescheduling proposal changes none of this.